Global HIV Antivirals Market Growth 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
HIV antivirals are medications used to manage HIV infection by inhibiting the virus's ability to replicate and spread. They work by targeting different stages of the HIV life cycle. These drugs are often used in combination to effectively control the virus and improve the quality of life for people living with HIV.
The global HIV Antivirals market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “HIV Antivirals Industry Forecast” looks at past sales and reviews total world HIV Antivirals sales in 2023, providing a comprehensive analysis by region and market sector of projected HIV Antivirals sales for 2024 through 2030. With HIV Antivirals sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world HIV Antivirals industry.
This Insight Report provides a comprehensive analysis of the global HIV Antivirals landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on HIV Antivirals portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global HIV Antivirals market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for HIV Antivirals and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global HIV Antivirals.
United States market for HIV Antivirals is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for HIV Antivirals is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for HIV Antivirals is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key HIV Antivirals players cover Gilead Sciences, ViiV Healthcare, Johnson & Johnson (Janssen Pharmaceuticals), Merck & Co., AbbVie, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of HIV Antivirals market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global HIV Antivirals market?
What factors are driving HIV Antivirals market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do HIV Antivirals market opportunities vary by end market size?
How does HIV Antivirals break out by Type, by Application?
HIV antivirals are medications used to manage HIV infection by inhibiting the virus's ability to replicate and spread. They work by targeting different stages of the HIV life cycle. These drugs are often used in combination to effectively control the virus and improve the quality of life for people living with HIV.
The global HIV Antivirals market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “HIV Antivirals Industry Forecast” looks at past sales and reviews total world HIV Antivirals sales in 2023, providing a comprehensive analysis by region and market sector of projected HIV Antivirals sales for 2024 through 2030. With HIV Antivirals sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world HIV Antivirals industry.
This Insight Report provides a comprehensive analysis of the global HIV Antivirals landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on HIV Antivirals portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global HIV Antivirals market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for HIV Antivirals and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global HIV Antivirals.
United States market for HIV Antivirals is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for HIV Antivirals is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for HIV Antivirals is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key HIV Antivirals players cover Gilead Sciences, ViiV Healthcare, Johnson & Johnson (Janssen Pharmaceuticals), Merck & Co., AbbVie, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of HIV Antivirals market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Fixed Dose Combinations (FDCs)
- Integrase Strand Transfer Inhibitors (lNSTls)
- Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTls)
- Entry Inhibitors -CCR5 co-receptor antagonist
- Protease Inhibitors (Pls)
- Nucleoside Reverse Transcriptase lnhibitors (NRTls)
- Others
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Gilead Sciences
- ViiV Healthcare
- Johnson & Johnson (Janssen Pharmaceuticals)
- Merck & Co.
- AbbVie
- Bristol-Myers Squibb
- Roche
- Teva Pharmaceuticals
What is the 10-year outlook for the global HIV Antivirals market?
What factors are driving HIV Antivirals market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do HIV Antivirals market opportunities vary by end market size?
How does HIV Antivirals break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global HIV Antivirals Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for HIV Antivirals by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for HIV Antivirals by Country/Region, 2019, 2023 & 2030
2.2 HIV Antivirals Segment by Type
2.2.1 Fixed Dose Combinations (FDCs)
2.2.2 Integrase Strand Transfer Inhibitors (lNSTls)
2.2.3 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTls)
2.2.4 Entry Inhibitors -CCR5 co-receptor antagonist
2.2.5 Protease Inhibitors (Pls)
2.2.6 Nucleoside Reverse Transcriptase lnhibitors (NRTls)
2.2.7 Others
2.3 HIV Antivirals Sales by Type
2.3.1 Global HIV Antivirals Sales Market Share by Type (2019-2024)
2.3.2 Global HIV Antivirals Revenue and Market Share by Type (2019-2024)
2.3.3 Global HIV Antivirals Sale Price by Type (2019-2024)
2.4 HIV Antivirals Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Retail Pharmacies
2.4.3 Online Pharmacies
2.5 HIV Antivirals Sales by Application
2.5.1 Global HIV Antivirals Sale Market Share by Application (2019-2024)
2.5.2 Global HIV Antivirals Revenue and Market Share by Application (2019-2024)
2.5.3 Global HIV Antivirals Sale Price by Application (2019-2024)
3 GLOBAL BY COMPANY
3.1 Global HIV Antivirals Breakdown Data by Company
3.1.1 Global HIV Antivirals Annual Sales by Company (2019-2024)
3.1.2 Global HIV Antivirals Sales Market Share by Company (2019-2024)
3.2 Global HIV Antivirals Annual Revenue by Company (2019-2024)
3.2.1 Global HIV Antivirals Revenue by Company (2019-2024)
3.2.2 Global HIV Antivirals Revenue Market Share by Company (2019-2024)
3.3 Global HIV Antivirals Sale Price by Company
3.4 Key Manufacturers HIV Antivirals Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers HIV Antivirals Product Location Distribution
3.4.2 Players HIV Antivirals Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR HIV ANTIVIRALS BY GEOGRAPHIC REGION
4.1 World Historic HIV Antivirals Market Size by Geographic Region (2019-2024)
4.1.1 Global HIV Antivirals Annual Sales by Geographic Region (2019-2024)
4.1.2 Global HIV Antivirals Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic HIV Antivirals Market Size by Country/Region (2019-2024)
4.2.1 Global HIV Antivirals Annual Sales by Country/Region (2019-2024)
4.2.2 Global HIV Antivirals Annual Revenue by Country/Region (2019-2024)
4.3 Americas HIV Antivirals Sales Growth
4.4 APAC HIV Antivirals Sales Growth
4.5 Europe HIV Antivirals Sales Growth
4.6 Middle East & Africa HIV Antivirals Sales Growth
5 AMERICAS
5.1 Americas HIV Antivirals Sales by Country
5.1.1 Americas HIV Antivirals Sales by Country (2019-2024)
5.1.2 Americas HIV Antivirals Revenue by Country (2019-2024)
5.2 Americas HIV Antivirals Sales by Type (2019-2024)
5.3 Americas HIV Antivirals Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC HIV Antivirals Sales by Region
6.1.1 APAC HIV Antivirals Sales by Region (2019-2024)
6.1.2 APAC HIV Antivirals Revenue by Region (2019-2024)
6.2 APAC HIV Antivirals Sales by Type (2019-2024)
6.3 APAC HIV Antivirals Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe HIV Antivirals by Country
7.1.1 Europe HIV Antivirals Sales by Country (2019-2024)
7.1.2 Europe HIV Antivirals Revenue by Country (2019-2024)
7.2 Europe HIV Antivirals Sales by Type (2019-2024)
7.3 Europe HIV Antivirals Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa HIV Antivirals by Country
8.1.1 Middle East & Africa HIV Antivirals Sales by Country (2019-2024)
8.1.2 Middle East & Africa HIV Antivirals Revenue by Country (2019-2024)
8.2 Middle East & Africa HIV Antivirals Sales by Type (2019-2024)
8.3 Middle East & Africa HIV Antivirals Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of HIV Antivirals
10.3 Manufacturing Process Analysis of HIV Antivirals
10.4 Industry Chain Structure of HIV Antivirals
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 HIV Antivirals Distributors
11.3 HIV Antivirals Customer
12 WORLD FORECAST REVIEW FOR HIV ANTIVIRALS BY GEOGRAPHIC REGION
12.1 Global HIV Antivirals Market Size Forecast by Region
12.1.1 Global HIV Antivirals Forecast by Region (2025-2030)
12.1.2 Global HIV Antivirals Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global HIV Antivirals Forecast by Type (2025-2030)
12.7 Global HIV Antivirals Forecast by Application (2025-2030)
13 KEY PLAYERS ANALYSIS
13.1 Gilead Sciences
13.1.1 Gilead Sciences Company Information
13.1.2 Gilead Sciences HIV Antivirals Product Portfolios and Specifications
13.1.3 Gilead Sciences HIV Antivirals Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Gilead Sciences Main Business Overview
13.1.5 Gilead Sciences Latest Developments
13.2 ViiV Healthcare
13.2.1 ViiV Healthcare Company Information
13.2.2 ViiV Healthcare HIV Antivirals Product Portfolios and Specifications
13.2.3 ViiV Healthcare HIV Antivirals Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 ViiV Healthcare Main Business Overview
13.2.5 ViiV Healthcare Latest Developments
13.3 Johnson & Johnson (Janssen Pharmaceuticals)
13.3.1 Johnson & Johnson (Janssen Pharmaceuticals) Company Information
13.3.2 Johnson & Johnson (Janssen Pharmaceuticals) HIV Antivirals Product Portfolios and Specifications
13.3.3 Johnson & Johnson (Janssen Pharmaceuticals) HIV Antivirals Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Johnson & Johnson (Janssen Pharmaceuticals) Main Business Overview
13.3.5 Johnson & Johnson (Janssen Pharmaceuticals) Latest Developments
13.4 Merck & Co.
13.4.1 Merck & Co. Company Information
13.4.2 Merck & Co. HIV Antivirals Product Portfolios and Specifications
13.4.3 Merck & Co. HIV Antivirals Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Merck & Co. Main Business Overview
13.4.5 Merck & Co. Latest Developments
13.5 AbbVie
13.5.1 AbbVie Company Information
13.5.2 AbbVie HIV Antivirals Product Portfolios and Specifications
13.5.3 AbbVie HIV Antivirals Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 AbbVie Main Business Overview
13.5.5 AbbVie Latest Developments
13.6 Bristol-Myers Squibb
13.6.1 Bristol-Myers Squibb Company Information
13.6.2 Bristol-Myers Squibb HIV Antivirals Product Portfolios and Specifications
13.6.3 Bristol-Myers Squibb HIV Antivirals Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Bristol-Myers Squibb Main Business Overview
13.6.5 Bristol-Myers Squibb Latest Developments
13.7 Roche
13.7.1 Roche Company Information
13.7.2 Roche HIV Antivirals Product Portfolios and Specifications
13.7.3 Roche HIV Antivirals Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Roche Main Business Overview
13.7.5 Roche Latest Developments
13.8 Teva Pharmaceuticals
13.8.1 Teva Pharmaceuticals Company Information
13.8.2 Teva Pharmaceuticals HIV Antivirals Product Portfolios and Specifications
13.8.3 Teva Pharmaceuticals HIV Antivirals Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Teva Pharmaceuticals Main Business Overview
13.8.5 Teva Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
.
Table 1. HIV Antivirals Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. HIV Antivirals Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players ofFixed Dose Combinations (FDCs)
Table 4. Major Players of Integrase StrandTransfer Inhibitors (lNSTls)
Table 5. Major Players of Non-Nucleoside ReverseTranscriptase Inhibitors (NNRTls)
Table 6. Major Players of Entry Inhibitors -CCR5 co-receptor antagonist
Table 7. Major Players of Protease Inhibitors (Pls)
Table 8. Major Players of Nucleoside ReverseTranscriptase lnhibitors (NRTls)
Table 9. Major Players of Others
Table 10. Global HIV Antivirals Sales byType (2019-2024) & (K Units)
Table 11. Global HIV Antivirals Sales Market Share byType (2019-2024)
Table 12. Global HIV Antivirals Revenue byType (2019-2024) & ($ million)
Table 13. Global HIV Antivirals Revenue Market Share byType (2019-2024)
Table 14. Global HIV Antivirals Sale Price byType (2019-2024) & (US$/Unit)
Table 15. Global HIV Antivirals Sale by Application (2019-2024) & (K Units)
Table 16. Global HIV Antivirals Sale Market Share by Application (2019-2024)
Table 17. Global HIV Antivirals Revenue by Application (2019-2024) & ($ million)
Table 18. Global HIV Antivirals Revenue Market Share by Application (2019-2024)
Table 19. Global HIV Antivirals Sale Price by Application (2019-2024) & (US$/Unit)
Table 20. Global HIV Antivirals Sales by Company (2019-2024) & (K Units)
Table 21. Global HIV Antivirals Sales Market Share by Company (2019-2024)
Table 22. Global HIV Antivirals Revenue by Company (2019-2024) & ($ millions)
Table 23. Global HIV Antivirals Revenue Market Share by Company (2019-2024)
Table 24. Global HIV Antivirals Sale Price by Company (2019-2024) & (US$/Unit)
Table 25. Key Manufacturers HIV Antivirals Producing Area Distribution and Sales Area
Table 26. Players HIV Antivirals Products Offered
Table 27. HIV Antivirals Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 28. New Products and Potential Entrants
Table 29. Market M&A Activity & Strategy
Table 30. Global HIV Antivirals Sales by Geographic Region (2019-2024) & (K Units)
Table 31. Global HIV Antivirals Sales Market Share Geographic Region (2019-2024)
Table 32. Global HIV Antivirals Revenue by Geographic Region (2019-2024) & ($ millions)
Table 33. Global HIV Antivirals Revenue Market Share by Geographic Region (2019-2024)
Table 34. Global HIV Antivirals Sales by Country/Region (2019-2024) & (K Units)
Table 35. Global HIV Antivirals Sales Market Share by Country/Region (2019-2024)
Table 36. Global HIV Antivirals Revenue by Country/Region (2019-2024) & ($ millions)
Table 37. Global HIV Antivirals Revenue Market Share by Country/Region (2019-2024)
Table 38. Americas HIV Antivirals Sales by Country (2019-2024) & (K Units)
Table 39. Americas HIV Antivirals Sales Market Share by Country (2019-2024)
Table 40. Americas HIV Antivirals Revenue by Country (2019-2024) & ($ millions)
Table 41. Americas HIV Antivirals Sales byType (2019-2024) & (K Units)
Table 42. Americas HIV Antivirals Sales by Application (2019-2024) & (K Units)
Table 43. APAC HIV Antivirals Sales by Region (2019-2024) & (K Units)
Table 44. APAC HIV Antivirals Sales Market Share by Region (2019-2024)
Table 45. APAC HIV Antivirals Revenue by Region (2019-2024) & ($ millions)
Table 46. APAC HIV Antivirals Sales byType (2019-2024) & (K Units)
Table 47. APAC HIV Antivirals Sales by Application (2019-2024) & (K Units)
Table 48. Europe HIV Antivirals Sales by Country (2019-2024) & (K Units)
Table 49. Europe HIV Antivirals Revenue by Country (2019-2024) & ($ millions)
Table 50. Europe HIV Antivirals Sales byType (2019-2024) & (K Units)
Table 51. Europe HIV Antivirals Sales by Application (2019-2024) & (K Units)
Table 52. Middle East & Africa HIV Antivirals Sales by Country (2019-2024) & (K Units)
Table 53. Middle East & Africa HIV Antivirals Revenue Market Share by Country (2019-2024)
Table 54. Middle East & Africa HIV Antivirals Sales byType (2019-2024) & (K Units)
Table 55. Middle East & Africa HIV Antivirals Sales by Application (2019-2024) & (K Units)
Table 56. Key Market Drivers & Growth Opportunities of HIV Antivirals
Table 57. Key Market Challenges & Risks of HIV Antivirals
Table 58. Key IndustryTrends of HIV Antivirals
Table 59. HIV Antivirals Raw Material
Table 60. Key Suppliers of Raw Materials
Table 61. HIV Antivirals Distributors List
Table 62. HIV Antivirals Customer List
Table 63. Global HIV Antivirals SalesForecast by Region (2025-2030) & (K Units)
Table 64. Global HIV Antivirals RevenueForecast by Region (2025-2030) & ($ millions)
Table 65. Americas HIV Antivirals SalesForecast by Country (2025-2030) & (K Units)
Table 66. Americas HIV Antivirals Annual RevenueForecast by Country (2025-2030) & ($ millions)
Table 67. APAC HIV Antivirals SalesForecast by Region (2025-2030) & (K Units)
Table 68. APAC HIV Antivirals Annual RevenueForecast by Region (2025-2030) & ($ millions)
Table 69. Europe HIV Antivirals SalesForecast by Country (2025-2030) & (K Units)
Table 70. Europe HIV Antivirals RevenueForecast by Country (2025-2030) & ($ millions)
Table 71. Middle East & Africa HIV Antivirals SalesForecast by Country (2025-2030) & (K Units)
Table 72. Middle East & Africa HIV Antivirals RevenueForecast by Country (2025-2030) & ($ millions)
Table 73. Global HIV Antivirals SalesForecast byType (2025-2030) & (K Units)
Table 74. Global HIV Antivirals RevenueForecast byType (2025-2030) & ($ millions)
Table 75. Global HIV Antivirals SalesForecast by Application (2025-2030) & (K Units)
Table 76. Global HIV Antivirals RevenueForecast by Application (2025-2030) & ($ millions)
Table 77. Gilead Sciences Basic Information, HIV Antivirals Manufacturing Base, Sales Area and Its Competitors
Table 78. Gilead Sciences HIV Antivirals Product Portfolios and Specifications
Table 79. Gilead Sciences HIV Antivirals Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 80. Gilead Sciences Main Business
Table 81. Gilead Sciences Latest Developments
Table 82. ViiV Healthcare Basic Information, HIV Antivirals Manufacturing Base, Sales Area and Its Competitors
Table 83. ViiV Healthcare HIV Antivirals Product Portfolios and Specifications
Table 84. ViiV Healthcare HIV Antivirals Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 85. ViiV Healthcare Main Business
Table 86. ViiV Healthcare Latest Developments
Table 87. Johnson & Johnson (Janssen Pharmaceuticals) Basic Information, HIV Antivirals Manufacturing Base, Sales Area and Its Competitors
Table 88. Johnson & Johnson (Janssen Pharmaceuticals) HIV Antivirals Product Portfolios and Specifications
Table 89. Johnson & Johnson (Janssen Pharmaceuticals) HIV Antivirals Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 90. Johnson & Johnson (Janssen Pharmaceuticals) Main Business
Table 91. Johnson & Johnson (Janssen Pharmaceuticals) Latest Developments
Table 92. Merck & Co. Basic Information, HIV Antivirals Manufacturing Base, Sales Area and Its Competitors
Table 93. Merck & Co. HIV Antivirals Product Portfolios and Specifications
Table 94. Merck & Co. HIV Antivirals Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 95. Merck & Co. Main Business
Table 96. Merck & Co. Latest Developments
Table 97. AbbVie Basic Information, HIV Antivirals Manufacturing Base, Sales Area and Its Competitors
Table 98. AbbVie HIV Antivirals Product Portfolios and Specifications
Table 99. AbbVie HIV Antivirals Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 100. AbbVie Main Business
Table 101. AbbVie Latest Developments
Table 102. Bristol-Myers Squibb Basic Information, HIV Antivirals Manufacturing Base, Sales Area and Its Competitors
Table 103. Bristol-Myers Squibb HIV Antivirals Product Portfolios and Specifications
Table 104. Bristol-Myers Squibb HIV Antivirals Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 105. Bristol-Myers Squibb Main Business
Table 106. Bristol-Myers Squibb Latest Developments
Table 107. Roche Basic Information, HIV Antivirals Manufacturing Base, Sales Area and Its Competitors
Table 108. Roche HIV Antivirals Product Portfolios and Specifications
Table 109. Roche HIV Antivirals Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 110. Roche Main Business
Table 111. Roche Latest Developments
Table 112.Teva Pharmaceuticals Basic Information, HIV Antivirals Manufacturing Base, Sales Area and Its Competitors
Table 113.Teva Pharmaceuticals HIV Antivirals Product Portfolios and Specifications
Table 114.Teva Pharmaceuticals HIV Antivirals Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 115.Teva Pharmaceuticals Main Business
Table 116.Teva Pharmaceuticals Latest Developments
LIST OFFIGURES
.
Figure 1. Picture of HIV Antivirals
Figure 2. HIV Antivirals Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global HIV Antivirals Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global HIV Antivirals Revenue Growth Rate 2019-2030 ($ millions)
Figure 8. HIV Antivirals Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 9. HIV Antivirals Sales Market Share by Country/Region (2023)
Figure 10. HIV Antivirals Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 11. Product Picture ofFixed Dose Combinations (FDCs)
Figure 12. Product Picture of Integrase StrandTransfer Inhibitors (lNSTls)
Figure 13. Product Picture of Non-Nucleoside ReverseTranscriptase Inhibitors (NNRTls)
Figure 14. Product Picture of Entry Inhibitors -CCR5 co-receptor antagonist
Figure 15. Product Picture of Protease Inhibitors (Pls)
Figure 16. Product Picture of Nucleoside ReverseTranscriptase lnhibitors (NRTls)
Figure 17. Product Picture of Others
Figure 18. Global HIV Antivirals Sales Market Share byType in 2023
Figure 19. Global HIV Antivirals Revenue Market Share byType (2019-2024)
Figure 20. HIV Antivirals Consumed in Hospital Pharmacies
Figure 21. Global HIV Antivirals Market: Hospital Pharmacies (2019-2024) & (K Units)
Figure 22. HIV Antivirals Consumed in Retail Pharmacies
Figure 23. Global HIV Antivirals Market: Retail Pharmacies (2019-2024) & (K Units)
Figure 24. HIV Antivirals Consumed in Online Pharmacies
Figure 25. Global HIV Antivirals Market: Online Pharmacies (2019-2024) & (K Units)
Figure 26. Global HIV Antivirals Sale Market Share by Application (2023)
Figure 27. Global HIV Antivirals Revenue Market Share by Application in 2023
Figure 28. HIV Antivirals Sales by Company in 2023 (K Units)
Figure 29. Global HIV Antivirals Sales Market Share by Company in 2023
Figure 30. HIV Antivirals Revenue by Company in 2023 ($ millions)
Figure 31. Global HIV Antivirals Revenue Market Share by Company in 2023
Figure 32. Global HIV Antivirals Sales Market Share by Geographic Region (2019-2024)
Figure 33. Global HIV Antivirals Revenue Market Share by Geographic Region in 2023
Figure 34. Americas HIV Antivirals Sales 2019-2024 (K Units)
Figure 35. Americas HIV Antivirals Revenue 2019-2024 ($ millions)
Figure 36. APAC HIV Antivirals Sales 2019-2024 (K Units)
Figure 37. APAC HIV Antivirals Revenue 2019-2024 ($ millions)
Figure 38. Europe HIV Antivirals Sales 2019-2024 (K Units)
Figure 39. Europe HIV Antivirals Revenue 2019-2024 ($ millions)
Figure 40. Middle East & Africa HIV Antivirals Sales 2019-2024 (K Units)
Figure 41. Middle East & Africa HIV Antivirals Revenue 2019-2024 ($ millions)
Figure 42. Americas HIV Antivirals Sales Market Share by Country in 2023
Figure 43. Americas HIV Antivirals Revenue Market Share by Country (2019-2024)
Figure 44. Americas HIV Antivirals Sales Market Share byType (2019-2024)
Figure 45. Americas HIV Antivirals Sales Market Share by Application (2019-2024)
Figure 46. United States HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 47. Canada HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 48. Mexico HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 49. Brazil HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 50. APAC HIV Antivirals Sales Market Share by Region in 2023
Figure 51. APAC HIV Antivirals Revenue Market Share by Region (2019-2024)
Figure 52. APAC HIV Antivirals Sales Market Share byType (2019-2024)
Figure 53. APAC HIV Antivirals Sales Market Share by Application (2019-2024)
Figure 54. China HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 55. Japan HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 56. South Korea HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 57. Southeast Asia HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 58. India HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 59. Australia HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 60. ChinaTaiwan HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 61. Europe HIV Antivirals Sales Market Share by Country in 2023
Figure 62. Europe HIV Antivirals Revenue Market Share by Country (2019-2024)
Figure 63. Europe HIV Antivirals Sales Market Share byType (2019-2024)
Figure 64. Europe HIV Antivirals Sales Market Share by Application (2019-2024)
Figure 65. Germany HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 66.France HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 67. UK HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 68. Italy HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 69. Russia HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 70. Middle East & Africa HIV Antivirals Sales Market Share by Country (2019-2024)
Figure 71. Middle East & Africa HIV Antivirals Sales Market Share byType (2019-2024)
Figure 72. Middle East & Africa HIV Antivirals Sales Market Share by Application (2019-2024)
Figure 73. Egypt HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 74. South Africa HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 75. Israel HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 76.Turkey HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 77. GCC Countries HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 78. Manufacturing Cost Structure Analysis of HIV Antivirals in 2023
Figure 79. Manufacturing Process Analysis of HIV Antivirals
Figure 80. Industry Chain Structure of HIV Antivirals
Figure 81. Channels of Distribution
Figure 82. Global HIV Antivirals Sales MarketForecast by Region (2025-2030)
Figure 83. Global HIV Antivirals Revenue Market ShareForecast by Region (2025-2030)
Figure 84. Global HIV Antivirals Sales Market ShareForecast byType (2025-2030)
Figure 85. Global HIV Antivirals Revenue Market ShareForecast byType (2025-2030)
Figure 86. Global HIV Antivirals Sales Market ShareForecast by Application (2025-2030)
Figure 87. Global HIV Antivirals Revenue Market ShareForecast by Application (2025-2030)
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global HIV Antivirals Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for HIV Antivirals by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for HIV Antivirals by Country/Region, 2019, 2023 & 2030
2.2 HIV Antivirals Segment by Type
2.2.1 Fixed Dose Combinations (FDCs)
2.2.2 Integrase Strand Transfer Inhibitors (lNSTls)
2.2.3 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTls)
2.2.4 Entry Inhibitors -CCR5 co-receptor antagonist
2.2.5 Protease Inhibitors (Pls)
2.2.6 Nucleoside Reverse Transcriptase lnhibitors (NRTls)
2.2.7 Others
2.3 HIV Antivirals Sales by Type
2.3.1 Global HIV Antivirals Sales Market Share by Type (2019-2024)
2.3.2 Global HIV Antivirals Revenue and Market Share by Type (2019-2024)
2.3.3 Global HIV Antivirals Sale Price by Type (2019-2024)
2.4 HIV Antivirals Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Retail Pharmacies
2.4.3 Online Pharmacies
2.5 HIV Antivirals Sales by Application
2.5.1 Global HIV Antivirals Sale Market Share by Application (2019-2024)
2.5.2 Global HIV Antivirals Revenue and Market Share by Application (2019-2024)
2.5.3 Global HIV Antivirals Sale Price by Application (2019-2024)
3 GLOBAL BY COMPANY
3.1 Global HIV Antivirals Breakdown Data by Company
3.1.1 Global HIV Antivirals Annual Sales by Company (2019-2024)
3.1.2 Global HIV Antivirals Sales Market Share by Company (2019-2024)
3.2 Global HIV Antivirals Annual Revenue by Company (2019-2024)
3.2.1 Global HIV Antivirals Revenue by Company (2019-2024)
3.2.2 Global HIV Antivirals Revenue Market Share by Company (2019-2024)
3.3 Global HIV Antivirals Sale Price by Company
3.4 Key Manufacturers HIV Antivirals Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers HIV Antivirals Product Location Distribution
3.4.2 Players HIV Antivirals Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR HIV ANTIVIRALS BY GEOGRAPHIC REGION
4.1 World Historic HIV Antivirals Market Size by Geographic Region (2019-2024)
4.1.1 Global HIV Antivirals Annual Sales by Geographic Region (2019-2024)
4.1.2 Global HIV Antivirals Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic HIV Antivirals Market Size by Country/Region (2019-2024)
4.2.1 Global HIV Antivirals Annual Sales by Country/Region (2019-2024)
4.2.2 Global HIV Antivirals Annual Revenue by Country/Region (2019-2024)
4.3 Americas HIV Antivirals Sales Growth
4.4 APAC HIV Antivirals Sales Growth
4.5 Europe HIV Antivirals Sales Growth
4.6 Middle East & Africa HIV Antivirals Sales Growth
5 AMERICAS
5.1 Americas HIV Antivirals Sales by Country
5.1.1 Americas HIV Antivirals Sales by Country (2019-2024)
5.1.2 Americas HIV Antivirals Revenue by Country (2019-2024)
5.2 Americas HIV Antivirals Sales by Type (2019-2024)
5.3 Americas HIV Antivirals Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC HIV Antivirals Sales by Region
6.1.1 APAC HIV Antivirals Sales by Region (2019-2024)
6.1.2 APAC HIV Antivirals Revenue by Region (2019-2024)
6.2 APAC HIV Antivirals Sales by Type (2019-2024)
6.3 APAC HIV Antivirals Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe HIV Antivirals by Country
7.1.1 Europe HIV Antivirals Sales by Country (2019-2024)
7.1.2 Europe HIV Antivirals Revenue by Country (2019-2024)
7.2 Europe HIV Antivirals Sales by Type (2019-2024)
7.3 Europe HIV Antivirals Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa HIV Antivirals by Country
8.1.1 Middle East & Africa HIV Antivirals Sales by Country (2019-2024)
8.1.2 Middle East & Africa HIV Antivirals Revenue by Country (2019-2024)
8.2 Middle East & Africa HIV Antivirals Sales by Type (2019-2024)
8.3 Middle East & Africa HIV Antivirals Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of HIV Antivirals
10.3 Manufacturing Process Analysis of HIV Antivirals
10.4 Industry Chain Structure of HIV Antivirals
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 HIV Antivirals Distributors
11.3 HIV Antivirals Customer
12 WORLD FORECAST REVIEW FOR HIV ANTIVIRALS BY GEOGRAPHIC REGION
12.1 Global HIV Antivirals Market Size Forecast by Region
12.1.1 Global HIV Antivirals Forecast by Region (2025-2030)
12.1.2 Global HIV Antivirals Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global HIV Antivirals Forecast by Type (2025-2030)
12.7 Global HIV Antivirals Forecast by Application (2025-2030)
13 KEY PLAYERS ANALYSIS
13.1 Gilead Sciences
13.1.1 Gilead Sciences Company Information
13.1.2 Gilead Sciences HIV Antivirals Product Portfolios and Specifications
13.1.3 Gilead Sciences HIV Antivirals Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Gilead Sciences Main Business Overview
13.1.5 Gilead Sciences Latest Developments
13.2 ViiV Healthcare
13.2.1 ViiV Healthcare Company Information
13.2.2 ViiV Healthcare HIV Antivirals Product Portfolios and Specifications
13.2.3 ViiV Healthcare HIV Antivirals Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 ViiV Healthcare Main Business Overview
13.2.5 ViiV Healthcare Latest Developments
13.3 Johnson & Johnson (Janssen Pharmaceuticals)
13.3.1 Johnson & Johnson (Janssen Pharmaceuticals) Company Information
13.3.2 Johnson & Johnson (Janssen Pharmaceuticals) HIV Antivirals Product Portfolios and Specifications
13.3.3 Johnson & Johnson (Janssen Pharmaceuticals) HIV Antivirals Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Johnson & Johnson (Janssen Pharmaceuticals) Main Business Overview
13.3.5 Johnson & Johnson (Janssen Pharmaceuticals) Latest Developments
13.4 Merck & Co.
13.4.1 Merck & Co. Company Information
13.4.2 Merck & Co. HIV Antivirals Product Portfolios and Specifications
13.4.3 Merck & Co. HIV Antivirals Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Merck & Co. Main Business Overview
13.4.5 Merck & Co. Latest Developments
13.5 AbbVie
13.5.1 AbbVie Company Information
13.5.2 AbbVie HIV Antivirals Product Portfolios and Specifications
13.5.3 AbbVie HIV Antivirals Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 AbbVie Main Business Overview
13.5.5 AbbVie Latest Developments
13.6 Bristol-Myers Squibb
13.6.1 Bristol-Myers Squibb Company Information
13.6.2 Bristol-Myers Squibb HIV Antivirals Product Portfolios and Specifications
13.6.3 Bristol-Myers Squibb HIV Antivirals Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Bristol-Myers Squibb Main Business Overview
13.6.5 Bristol-Myers Squibb Latest Developments
13.7 Roche
13.7.1 Roche Company Information
13.7.2 Roche HIV Antivirals Product Portfolios and Specifications
13.7.3 Roche HIV Antivirals Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Roche Main Business Overview
13.7.5 Roche Latest Developments
13.8 Teva Pharmaceuticals
13.8.1 Teva Pharmaceuticals Company Information
13.8.2 Teva Pharmaceuticals HIV Antivirals Product Portfolios and Specifications
13.8.3 Teva Pharmaceuticals HIV Antivirals Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Teva Pharmaceuticals Main Business Overview
13.8.5 Teva Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
.
Table 1. HIV Antivirals Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. HIV Antivirals Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players ofFixed Dose Combinations (FDCs)
Table 4. Major Players of Integrase StrandTransfer Inhibitors (lNSTls)
Table 5. Major Players of Non-Nucleoside ReverseTranscriptase Inhibitors (NNRTls)
Table 6. Major Players of Entry Inhibitors -CCR5 co-receptor antagonist
Table 7. Major Players of Protease Inhibitors (Pls)
Table 8. Major Players of Nucleoside ReverseTranscriptase lnhibitors (NRTls)
Table 9. Major Players of Others
Table 10. Global HIV Antivirals Sales byType (2019-2024) & (K Units)
Table 11. Global HIV Antivirals Sales Market Share byType (2019-2024)
Table 12. Global HIV Antivirals Revenue byType (2019-2024) & ($ million)
Table 13. Global HIV Antivirals Revenue Market Share byType (2019-2024)
Table 14. Global HIV Antivirals Sale Price byType (2019-2024) & (US$/Unit)
Table 15. Global HIV Antivirals Sale by Application (2019-2024) & (K Units)
Table 16. Global HIV Antivirals Sale Market Share by Application (2019-2024)
Table 17. Global HIV Antivirals Revenue by Application (2019-2024) & ($ million)
Table 18. Global HIV Antivirals Revenue Market Share by Application (2019-2024)
Table 19. Global HIV Antivirals Sale Price by Application (2019-2024) & (US$/Unit)
Table 20. Global HIV Antivirals Sales by Company (2019-2024) & (K Units)
Table 21. Global HIV Antivirals Sales Market Share by Company (2019-2024)
Table 22. Global HIV Antivirals Revenue by Company (2019-2024) & ($ millions)
Table 23. Global HIV Antivirals Revenue Market Share by Company (2019-2024)
Table 24. Global HIV Antivirals Sale Price by Company (2019-2024) & (US$/Unit)
Table 25. Key Manufacturers HIV Antivirals Producing Area Distribution and Sales Area
Table 26. Players HIV Antivirals Products Offered
Table 27. HIV Antivirals Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 28. New Products and Potential Entrants
Table 29. Market M&A Activity & Strategy
Table 30. Global HIV Antivirals Sales by Geographic Region (2019-2024) & (K Units)
Table 31. Global HIV Antivirals Sales Market Share Geographic Region (2019-2024)
Table 32. Global HIV Antivirals Revenue by Geographic Region (2019-2024) & ($ millions)
Table 33. Global HIV Antivirals Revenue Market Share by Geographic Region (2019-2024)
Table 34. Global HIV Antivirals Sales by Country/Region (2019-2024) & (K Units)
Table 35. Global HIV Antivirals Sales Market Share by Country/Region (2019-2024)
Table 36. Global HIV Antivirals Revenue by Country/Region (2019-2024) & ($ millions)
Table 37. Global HIV Antivirals Revenue Market Share by Country/Region (2019-2024)
Table 38. Americas HIV Antivirals Sales by Country (2019-2024) & (K Units)
Table 39. Americas HIV Antivirals Sales Market Share by Country (2019-2024)
Table 40. Americas HIV Antivirals Revenue by Country (2019-2024) & ($ millions)
Table 41. Americas HIV Antivirals Sales byType (2019-2024) & (K Units)
Table 42. Americas HIV Antivirals Sales by Application (2019-2024) & (K Units)
Table 43. APAC HIV Antivirals Sales by Region (2019-2024) & (K Units)
Table 44. APAC HIV Antivirals Sales Market Share by Region (2019-2024)
Table 45. APAC HIV Antivirals Revenue by Region (2019-2024) & ($ millions)
Table 46. APAC HIV Antivirals Sales byType (2019-2024) & (K Units)
Table 47. APAC HIV Antivirals Sales by Application (2019-2024) & (K Units)
Table 48. Europe HIV Antivirals Sales by Country (2019-2024) & (K Units)
Table 49. Europe HIV Antivirals Revenue by Country (2019-2024) & ($ millions)
Table 50. Europe HIV Antivirals Sales byType (2019-2024) & (K Units)
Table 51. Europe HIV Antivirals Sales by Application (2019-2024) & (K Units)
Table 52. Middle East & Africa HIV Antivirals Sales by Country (2019-2024) & (K Units)
Table 53. Middle East & Africa HIV Antivirals Revenue Market Share by Country (2019-2024)
Table 54. Middle East & Africa HIV Antivirals Sales byType (2019-2024) & (K Units)
Table 55. Middle East & Africa HIV Antivirals Sales by Application (2019-2024) & (K Units)
Table 56. Key Market Drivers & Growth Opportunities of HIV Antivirals
Table 57. Key Market Challenges & Risks of HIV Antivirals
Table 58. Key IndustryTrends of HIV Antivirals
Table 59. HIV Antivirals Raw Material
Table 60. Key Suppliers of Raw Materials
Table 61. HIV Antivirals Distributors List
Table 62. HIV Antivirals Customer List
Table 63. Global HIV Antivirals SalesForecast by Region (2025-2030) & (K Units)
Table 64. Global HIV Antivirals RevenueForecast by Region (2025-2030) & ($ millions)
Table 65. Americas HIV Antivirals SalesForecast by Country (2025-2030) & (K Units)
Table 66. Americas HIV Antivirals Annual RevenueForecast by Country (2025-2030) & ($ millions)
Table 67. APAC HIV Antivirals SalesForecast by Region (2025-2030) & (K Units)
Table 68. APAC HIV Antivirals Annual RevenueForecast by Region (2025-2030) & ($ millions)
Table 69. Europe HIV Antivirals SalesForecast by Country (2025-2030) & (K Units)
Table 70. Europe HIV Antivirals RevenueForecast by Country (2025-2030) & ($ millions)
Table 71. Middle East & Africa HIV Antivirals SalesForecast by Country (2025-2030) & (K Units)
Table 72. Middle East & Africa HIV Antivirals RevenueForecast by Country (2025-2030) & ($ millions)
Table 73. Global HIV Antivirals SalesForecast byType (2025-2030) & (K Units)
Table 74. Global HIV Antivirals RevenueForecast byType (2025-2030) & ($ millions)
Table 75. Global HIV Antivirals SalesForecast by Application (2025-2030) & (K Units)
Table 76. Global HIV Antivirals RevenueForecast by Application (2025-2030) & ($ millions)
Table 77. Gilead Sciences Basic Information, HIV Antivirals Manufacturing Base, Sales Area and Its Competitors
Table 78. Gilead Sciences HIV Antivirals Product Portfolios and Specifications
Table 79. Gilead Sciences HIV Antivirals Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 80. Gilead Sciences Main Business
Table 81. Gilead Sciences Latest Developments
Table 82. ViiV Healthcare Basic Information, HIV Antivirals Manufacturing Base, Sales Area and Its Competitors
Table 83. ViiV Healthcare HIV Antivirals Product Portfolios and Specifications
Table 84. ViiV Healthcare HIV Antivirals Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 85. ViiV Healthcare Main Business
Table 86. ViiV Healthcare Latest Developments
Table 87. Johnson & Johnson (Janssen Pharmaceuticals) Basic Information, HIV Antivirals Manufacturing Base, Sales Area and Its Competitors
Table 88. Johnson & Johnson (Janssen Pharmaceuticals) HIV Antivirals Product Portfolios and Specifications
Table 89. Johnson & Johnson (Janssen Pharmaceuticals) HIV Antivirals Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 90. Johnson & Johnson (Janssen Pharmaceuticals) Main Business
Table 91. Johnson & Johnson (Janssen Pharmaceuticals) Latest Developments
Table 92. Merck & Co. Basic Information, HIV Antivirals Manufacturing Base, Sales Area and Its Competitors
Table 93. Merck & Co. HIV Antivirals Product Portfolios and Specifications
Table 94. Merck & Co. HIV Antivirals Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 95. Merck & Co. Main Business
Table 96. Merck & Co. Latest Developments
Table 97. AbbVie Basic Information, HIV Antivirals Manufacturing Base, Sales Area and Its Competitors
Table 98. AbbVie HIV Antivirals Product Portfolios and Specifications
Table 99. AbbVie HIV Antivirals Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 100. AbbVie Main Business
Table 101. AbbVie Latest Developments
Table 102. Bristol-Myers Squibb Basic Information, HIV Antivirals Manufacturing Base, Sales Area and Its Competitors
Table 103. Bristol-Myers Squibb HIV Antivirals Product Portfolios and Specifications
Table 104. Bristol-Myers Squibb HIV Antivirals Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 105. Bristol-Myers Squibb Main Business
Table 106. Bristol-Myers Squibb Latest Developments
Table 107. Roche Basic Information, HIV Antivirals Manufacturing Base, Sales Area and Its Competitors
Table 108. Roche HIV Antivirals Product Portfolios and Specifications
Table 109. Roche HIV Antivirals Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 110. Roche Main Business
Table 111. Roche Latest Developments
Table 112.Teva Pharmaceuticals Basic Information, HIV Antivirals Manufacturing Base, Sales Area and Its Competitors
Table 113.Teva Pharmaceuticals HIV Antivirals Product Portfolios and Specifications
Table 114.Teva Pharmaceuticals HIV Antivirals Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 115.Teva Pharmaceuticals Main Business
Table 116.Teva Pharmaceuticals Latest Developments
LIST OFFIGURES
.
Figure 1. Picture of HIV Antivirals
Figure 2. HIV Antivirals Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global HIV Antivirals Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global HIV Antivirals Revenue Growth Rate 2019-2030 ($ millions)
Figure 8. HIV Antivirals Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 9. HIV Antivirals Sales Market Share by Country/Region (2023)
Figure 10. HIV Antivirals Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 11. Product Picture ofFixed Dose Combinations (FDCs)
Figure 12. Product Picture of Integrase StrandTransfer Inhibitors (lNSTls)
Figure 13. Product Picture of Non-Nucleoside ReverseTranscriptase Inhibitors (NNRTls)
Figure 14. Product Picture of Entry Inhibitors -CCR5 co-receptor antagonist
Figure 15. Product Picture of Protease Inhibitors (Pls)
Figure 16. Product Picture of Nucleoside ReverseTranscriptase lnhibitors (NRTls)
Figure 17. Product Picture of Others
Figure 18. Global HIV Antivirals Sales Market Share byType in 2023
Figure 19. Global HIV Antivirals Revenue Market Share byType (2019-2024)
Figure 20. HIV Antivirals Consumed in Hospital Pharmacies
Figure 21. Global HIV Antivirals Market: Hospital Pharmacies (2019-2024) & (K Units)
Figure 22. HIV Antivirals Consumed in Retail Pharmacies
Figure 23. Global HIV Antivirals Market: Retail Pharmacies (2019-2024) & (K Units)
Figure 24. HIV Antivirals Consumed in Online Pharmacies
Figure 25. Global HIV Antivirals Market: Online Pharmacies (2019-2024) & (K Units)
Figure 26. Global HIV Antivirals Sale Market Share by Application (2023)
Figure 27. Global HIV Antivirals Revenue Market Share by Application in 2023
Figure 28. HIV Antivirals Sales by Company in 2023 (K Units)
Figure 29. Global HIV Antivirals Sales Market Share by Company in 2023
Figure 30. HIV Antivirals Revenue by Company in 2023 ($ millions)
Figure 31. Global HIV Antivirals Revenue Market Share by Company in 2023
Figure 32. Global HIV Antivirals Sales Market Share by Geographic Region (2019-2024)
Figure 33. Global HIV Antivirals Revenue Market Share by Geographic Region in 2023
Figure 34. Americas HIV Antivirals Sales 2019-2024 (K Units)
Figure 35. Americas HIV Antivirals Revenue 2019-2024 ($ millions)
Figure 36. APAC HIV Antivirals Sales 2019-2024 (K Units)
Figure 37. APAC HIV Antivirals Revenue 2019-2024 ($ millions)
Figure 38. Europe HIV Antivirals Sales 2019-2024 (K Units)
Figure 39. Europe HIV Antivirals Revenue 2019-2024 ($ millions)
Figure 40. Middle East & Africa HIV Antivirals Sales 2019-2024 (K Units)
Figure 41. Middle East & Africa HIV Antivirals Revenue 2019-2024 ($ millions)
Figure 42. Americas HIV Antivirals Sales Market Share by Country in 2023
Figure 43. Americas HIV Antivirals Revenue Market Share by Country (2019-2024)
Figure 44. Americas HIV Antivirals Sales Market Share byType (2019-2024)
Figure 45. Americas HIV Antivirals Sales Market Share by Application (2019-2024)
Figure 46. United States HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 47. Canada HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 48. Mexico HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 49. Brazil HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 50. APAC HIV Antivirals Sales Market Share by Region in 2023
Figure 51. APAC HIV Antivirals Revenue Market Share by Region (2019-2024)
Figure 52. APAC HIV Antivirals Sales Market Share byType (2019-2024)
Figure 53. APAC HIV Antivirals Sales Market Share by Application (2019-2024)
Figure 54. China HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 55. Japan HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 56. South Korea HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 57. Southeast Asia HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 58. India HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 59. Australia HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 60. ChinaTaiwan HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 61. Europe HIV Antivirals Sales Market Share by Country in 2023
Figure 62. Europe HIV Antivirals Revenue Market Share by Country (2019-2024)
Figure 63. Europe HIV Antivirals Sales Market Share byType (2019-2024)
Figure 64. Europe HIV Antivirals Sales Market Share by Application (2019-2024)
Figure 65. Germany HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 66.France HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 67. UK HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 68. Italy HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 69. Russia HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 70. Middle East & Africa HIV Antivirals Sales Market Share by Country (2019-2024)
Figure 71. Middle East & Africa HIV Antivirals Sales Market Share byType (2019-2024)
Figure 72. Middle East & Africa HIV Antivirals Sales Market Share by Application (2019-2024)
Figure 73. Egypt HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 74. South Africa HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 75. Israel HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 76.Turkey HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 77. GCC Countries HIV Antivirals Revenue Growth 2019-2024 ($ millions)
Figure 78. Manufacturing Cost Structure Analysis of HIV Antivirals in 2023
Figure 79. Manufacturing Process Analysis of HIV Antivirals
Figure 80. Industry Chain Structure of HIV Antivirals
Figure 81. Channels of Distribution
Figure 82. Global HIV Antivirals Sales MarketForecast by Region (2025-2030)
Figure 83. Global HIV Antivirals Revenue Market ShareForecast by Region (2025-2030)
Figure 84. Global HIV Antivirals Sales Market ShareForecast byType (2025-2030)
Figure 85. Global HIV Antivirals Revenue Market ShareForecast byType (2025-2030)
Figure 86. Global HIV Antivirals Sales Market ShareForecast by Application (2025-2030)
Figure 87. Global HIV Antivirals Revenue Market ShareForecast by Application (2025-2030)
